|
Apr 16
|
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
|
|
Apr 16
|
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
|
|
Mar 14
|
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
|
|
Feb 18
|
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
|
|
Apr 4
|
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
|
|
Jan 15
|
Basilea announces acquisition of preclinical antibiotics program from Spexis
|
|
Dec 20
|
Basilea announces accelerated loan repayment
|
|
Oct 2
|
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
|